A.O. Ordine Mauriziano di Torino

Titolo:	Evaluation of safety and tolerability of Roginolisib in combination with Ruxolitinib in Myelofibrosis
Codice studio	HEMA-MED
Patologia:	Mielofibrosi
Tipo di Studio:	Interventistico
Tipologia	Profit
Fase:	2
Principali criteri di inclusione:	• Diagnosis of MF, Post-Polycythaemia Vera Myelofibrosis MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF) • Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-1, intermediate-2, or high • Treated with ruxolitinib for ≥ 3 months with a stable dose ≥ 10 mg for a minimum of 8 weeks prior to Day 1. • patients must show an unsatisfactory spleen reduction, such as a reduction of less than 25%, and spleen must be palpable ≥ 10 cm below the left costal margin on physical examination
Principali criteri di esclusione:	• Receiving an immune-suppressive based treatment for any reason (including chronic use of systemic corticosteroid at doses > 10 mg/day prednisone equivalent)
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it